Compare General Motors Company (GM) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Motors Company vs Neurocrine Biosciences Inc — how do they compare? General Motors Company trades at $82.5 (market cap $71.06B), while Neurocrine Biosciences Inc trades at $141.09 (market cap $14.60B). The key difference: General Motors Company is far larger — about 4.9× Neurocrine Biosciences Inc's market cap, and General Motors Company pays a 0.89% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold General Motors Company for 83 Days and Neurocrine Biosciences Inc for 23 Days on average.
| GM | NBIX | |
|---|---|---|
Market Cap | $71.06B | $14.60B |
Volume | 6,269,264 | 1,075,694 |
Sector | Consumer Cyclical | Health |
52-Week High | $90.30 | $185.50 |
52-Week Low | $55.35 | $123.10 |
Typical Hold Time | 83 Days | 23 Days |
Enterprise Value | $174.04B | $14.61B |
Dividend Yield | 0.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Motors (GM) trades at $82.25, up 0.29% with a bearish technical signal despite recent earnings beats. The stock shows mixed fundamentals with declining revenue and net income margins (1.05% in 2025) but attractive valuation ratios including P/S of 0.41. Recent news highlights competitive pressures as Toyota narrows the U.S. sales gap and Q3 2026 sales fell 5.5% amid EV challenges.
GM faces headwinds from market share erosion and profitability pressure, though analyst consensus remains bullish with a $102.08 price target. Investment appeal hinges on execution amid industry transition, with risks including high debt levels and competitive threats from Asian automakers.
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, with a bearish technical signal but strong fundamentals including a 20.91% net income margin and consistent earnings beats. Recent news highlights pipeline advancements in Prader-Willi syndrome and executive appointments, while analyst consensus remains strongly bullish with a $204.18 price target.
The outlook is positive based on robust profitability and growth initiatives, though risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharma company with a deep pipeline, balanced by near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About General Motors Company
General Motors Co. emerged from the bankruptcy of General Motors Corp. (old GM) in July 2009. GM has eight brands and operates under four segments: GM North America, GM International, Cruise, and GM Financial. The United States now has four brands instead of eight under old GM. The company lost its U.S. market share leader crown in 2021 with share down 280 basis points to 14.6%, but we expect GM to reclaim the top spot in 2022 as 2021 suffered from the chip shortage. GM Financial became the company's captive finance arm in October 2010 via the purchase of AmeriCredit.
Read more on GM →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
